Dapagliflozin 10mg Tablet Uses:
- Dapagliflozin inhibition of SGLT2 results in daily urinary glucose excretion of Approximately 70g, providing:
- Significant and sustained HBA1c reductions versus placebo when added to metformin.
- Secondary benefit of weight loss.
- A selective inhibitors of sodium-glucose contransporter-2 (SGLT2).
- Improves hyperglycemia and facilitates weight loss in type 2 diabetic patients.
- Prolonged half life and produces consistent pharmacodynamic activity.
- Induces steady rates to glucosuria.
- Exhibits a diuretic effect.
